CR20190559A - Derivados de fenilo como moduladores del receptor de pge2 - Google Patents
Derivados de fenilo como moduladores del receptor de pge2Info
- Publication number
- CR20190559A CR20190559A CR20190559A CR20190559A CR20190559A CR 20190559 A CR20190559 A CR 20190559A CR 20190559 A CR20190559 A CR 20190559A CR 20190559 A CR20190559 A CR 20190559A CR 20190559 A CR20190559 A CR 20190559A
- Authority
- CR
- Costa Rica
- Prior art keywords
- formula
- phenyl derivatives
- receptor modulators
- pge2 receptor
- pharmaceuticals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
La presente invención se refiere a derivados de fenilo de fórmula (I) donde (R1)n, R3, R4a, R4b, R5a, R5b y Ar1 son como se describen en la descripción y su uso en el tratamiento del cáncer mediante la modulación de una respuesta inmune que comprende una reactivación del sistema inmune en el tumor. La invención se refiere además a nuevos derivados de benzofurano y benzotiofeno de fórmula (III) y su uso como productos farmacéuticos, a su preparación, a las sales aceptables para uso farmacéuticos de los mismos, y a su uso como productos farmacéuticos, a composiciones farmacéuticas que contienen uno o más compuestos de fórmula (I), y especialmente a su uso como moduladores de los receptores EP2 y/o EP4 de la prostaglandina 2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2017062031 | 2017-05-18 | ||
PCT/EP2018/062862 WO2018210994A1 (en) | 2017-05-18 | 2018-05-17 | Phenyl derivatives as pge2 receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20190559A true CR20190559A (es) | 2020-02-10 |
Family
ID=62186480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20190559A CR20190559A (es) | 2017-05-18 | 2018-05-17 | Derivados de fenilo como moduladores del receptor de pge2 |
Country Status (32)
Country | Link |
---|---|
US (1) | US11712438B2 (es) |
EP (1) | EP3625222B1 (es) |
JP (1) | JP7159214B2 (es) |
KR (1) | KR102632028B1 (es) |
CN (1) | CN110612296A (es) |
AR (1) | AR111941A1 (es) |
AU (1) | AU2018269666B2 (es) |
BR (1) | BR112019024109A2 (es) |
CA (1) | CA3060597A1 (es) |
CL (1) | CL2019003275A1 (es) |
CO (1) | CO2019010578A2 (es) |
CR (1) | CR20190559A (es) |
CY (1) | CY1124608T1 (es) |
DK (1) | DK3625222T3 (es) |
EA (1) | EA201992676A1 (es) |
ES (1) | ES2893452T3 (es) |
HR (1) | HRP20211533T1 (es) |
HU (1) | HUE056080T2 (es) |
IL (1) | IL270623B2 (es) |
LT (1) | LT3625222T (es) |
MA (1) | MA49126B1 (es) |
MX (1) | MX2019013718A (es) |
PE (1) | PE20191814A1 (es) |
PH (1) | PH12019502563A1 (es) |
PL (1) | PL3625222T3 (es) |
PT (1) | PT3625222T (es) |
RS (1) | RS62440B1 (es) |
SG (1) | SG11201908729UA (es) |
SI (1) | SI3625222T1 (es) |
TW (1) | TWI765041B (es) |
UA (1) | UA125123C2 (es) |
WO (1) | WO2018210994A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
WO2018210992A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
KR102626982B1 (ko) | 2017-05-18 | 2024-01-18 | 이도르시아 파마슈티컬스 리미티드 | Pge2 수용체 조절제로서의 피리미딘 유도체 |
JP7093791B2 (ja) | 2017-05-18 | 2022-06-30 | イドーシア ファーマシューティカルズ リミテッド | Pge2レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体 |
CA3086925A1 (en) | 2018-01-05 | 2019-07-11 | Ichan School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
EP3768267A4 (en) | 2018-03-20 | 2022-04-20 | Icahn School of Medicine at Mount Sinai | KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE |
CN113543783A (zh) * | 2018-12-31 | 2021-10-22 | 西奈山伊坎医学院 | 激酶抑制剂化合物和组合物及使用方法 |
WO2022102731A1 (ja) | 2020-11-13 | 2022-05-19 | 小野薬品工業株式会社 | Ep4拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療 |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
DE60038902D1 (de) | 2000-03-24 | 2008-06-26 | Asterand Uk Ltd | Verwendung von prostanoid-ep4-rezeptor-antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten |
HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
EP1495005A1 (en) | 2002-04-12 | 2005-01-12 | Pfizer Japan Inc. | Pyrazole compounds as anti-inflammatory and analgesic agents |
AU2003216579A1 (en) | 2002-04-12 | 2003-10-27 | Pfizer Inc. | Imidazole compounds as anti-inflammatory and analgesic agents |
AU2003233297A1 (en) | 2002-05-23 | 2003-12-12 | Theratechnologies Inc | Antagonistic peptides of prostaglandin e2 receptor subtype ep4 |
DK1603893T3 (da) | 2003-01-29 | 2008-09-08 | Asterand Uk Ltd | EP4 -Receptorantagonister |
TW200519116A (en) | 2003-08-26 | 2005-06-16 | Teijin Pharma Ltd | Pyrrolopyrimidine derivatives |
BRPI0414130B8 (pt) | 2003-09-03 | 2021-05-25 | Askat Inc | compostos de fenilamida ou piridilamida, seu uso e composições farmacêuticas que os compreendem. |
US8084457B2 (en) | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
KR20070006891A (ko) | 2004-05-04 | 2007-01-11 | 화이자 인코포레이티드 | 치환된 메틸 아릴 또는 헤테로아릴 아미드 화합물 |
ATE435198T1 (de) | 2004-05-04 | 2009-07-15 | Raqualia Pharma Inc | Orthosubstituierte aryl- oder heteroarylamidverbindungen |
HN2005000795A (es) | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
WO2006122403A1 (en) | 2005-05-19 | 2006-11-23 | Merck Frosst Canada Ltd. | Quinoline derivatives as ep4 antagonists |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
AR060403A1 (es) | 2006-04-12 | 2008-06-11 | Sanofi Aventis | Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2 |
WO2007121578A1 (en) | 2006-04-24 | 2007-11-01 | Merck Frosst Canada Ltd. | Indole amide derivatives as ep4 receptor antagonists |
WO2007143825A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
US7989458B2 (en) | 2006-07-14 | 2011-08-02 | Novartis Ag | Pyrimidine derivatives as alk-5 inhibitors |
US8969394B2 (en) | 2006-08-11 | 2015-03-03 | Merck Frosst Canada Ltd. | Thiophenecarboxamide derivatives as EP4 receptor ligands |
WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
AU2008221194B2 (en) | 2007-02-26 | 2013-06-27 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists |
US8003661B2 (en) | 2007-03-26 | 2011-08-23 | Merck Canada Inc. | Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists |
EP2141147A1 (en) | 2007-03-26 | 2010-01-06 | Astellas Pharma Inc. | Ornithine derivative |
EP2014657A1 (de) * | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidine als Modulatoren des EP2-Rezeptors |
EP2172447A4 (en) | 2007-07-03 | 2011-08-24 | Astellas Pharma Inc | amide |
ATE510827T1 (de) | 2007-10-12 | 2011-06-15 | Ingenium Pharmaceuticals Gmbh | Inhibitoren von proteinkinasen |
CA2714743C (en) | 2008-02-19 | 2017-01-17 | Janssen Pharmaceutica N.V. | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
AU2009247262B2 (en) | 2008-05-14 | 2013-01-31 | Astellas Pharma Inc. | Amide compound |
US20130225528A1 (en) | 2008-05-21 | 2013-08-29 | Ariad Pharmaceuticals, Inc. | Phosphorus Derivatives as Kinase Inhibitors |
CA2733247C (en) | 2008-08-14 | 2018-04-03 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as ep4 receptor antagonists |
CN102164942B (zh) | 2008-09-19 | 2017-02-15 | 生物科技研究有限公司 | 三萜系化合物及其使用的方法 |
AU2009295308A1 (en) | 2008-09-25 | 2010-04-01 | Merck Canada Inc. | Beta-carboline sulphonylurea derivatives as EP4 receptor antagonists |
US8906914B2 (en) | 2009-08-18 | 2014-12-09 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid hydrolase |
CN102711757A (zh) | 2009-11-23 | 2012-10-03 | 莱西肯医药有限公司 | 用于治疗肠易激综合征的方法和分析法 |
JP5607241B2 (ja) | 2010-05-21 | 2014-10-15 | ケミリア・エービー | 新規ピリミジン誘導体 |
JP5956448B2 (ja) | 2010-09-21 | 2016-07-27 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
KR101857310B1 (ko) | 2010-09-29 | 2018-05-11 | 가부시키가이샤 에누비 켄코우겡큐쇼 | 인간 프로스타글란딘 e2 수용체 ep4 에 대한 항체 |
AU2011331161A1 (en) | 2010-11-17 | 2013-05-02 | Novartis Ag | 3-(aminoaryl)-pyridine compounds |
WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
EP2649061B1 (en) | 2010-12-10 | 2015-05-13 | Rottapharm Biotech S.r.l. | Pyridine amide derivatives as ep4 receptor antagonists |
WO2012103071A2 (en) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
BR112013024378A2 (pt) | 2011-03-24 | 2016-12-13 | Chemilia Ab | novos derivados de pirimidina |
EP2702043A1 (en) | 2011-04-29 | 2014-03-05 | Exelixis, Inc. | Inhibitors of inducible form of 6-phosphofructose-2-kinase |
CA2839956A1 (en) | 2011-06-20 | 2012-12-27 | Emory University | Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto |
ES2559513T3 (es) | 2011-07-04 | 2016-02-12 | Rottapharm Biotech S.R.L. | Derivados de amina cíclica como antagonistas del receptor EP4 |
EP2554662A1 (en) | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Methods of treatment of retinal degeneration diseases |
US20150004175A1 (en) | 2011-12-13 | 2015-01-01 | Yale University | Compositions and Methods for Reducing CTL Exhaustion |
SI3459942T1 (sl) * | 2012-04-24 | 2021-05-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
TWI572597B (zh) | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基-苯甲酸化合物 |
JO3296B1 (ar) | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
EP2711364A1 (en) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
AU2013353542B2 (en) | 2012-11-27 | 2018-04-05 | Thomas Helledays Stiftelse For Medicinsk Forskning | Pyrimidine-2,4-diamine derivatives for treatment of cancer |
UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
EP2765128A1 (en) | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫-1h-異喹啉化合物 |
AU2014272718B2 (en) | 2013-05-30 | 2018-06-28 | Idorsia Pharmaceuticals Ltd | CXCR7 receptor modulators |
KR102212981B1 (ko) | 2013-06-12 | 2021-02-04 | 가껭세이야꾸가부시기가이샤 | 4-알키닐이미다졸 유도체 및 그것을 유효 성분으로서 함유하는 의약 |
PE20160432A1 (es) | 2013-09-04 | 2016-05-11 | Bristol Myers Squibb Co | Compuestos utiles como inmunomoduladores |
PL3363790T3 (pl) | 2013-09-06 | 2020-07-27 | Aurigene Discovery Technologies Limited | Pochodne 1,2,4-oksadiazolu jako immunomodulatory |
WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
RS60426B1 (sr) | 2013-10-17 | 2020-07-31 | Vertex Pharma | Kokristali (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)hinolin-4-karboksamida i njihovi deuterisani derivati kao inhibitori dnk-pk |
DK3057959T3 (en) * | 2013-10-17 | 2018-06-06 | Vertex Pharma | INHIBITORS FOR DNA PK |
ME03398B (me) | 2013-12-17 | 2020-01-20 | Lilly Co Eli | Spojevi dimetilbenzojeve kiseline |
AU2014366361B2 (en) | 2013-12-17 | 2017-04-20 | Eli Lilly And Company | Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators |
TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ep4配體之新穎苯并咪唑衍生物 |
TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
WO2015167825A1 (en) | 2014-04-29 | 2015-11-05 | Emory University | Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto |
CN106572993B (zh) | 2014-05-23 | 2019-07-16 | 卫材R&D管理有限公司 | Ep4拮抗剂在制备治疗癌症的药物中的应用 |
AU2015268962A1 (en) | 2014-06-04 | 2017-01-12 | Thomas Helledays Stiftelse For Medicinsk Forskning | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions |
GEP20197011B (en) | 2014-06-19 | 2019-08-12 | Ariad Pharma Inc | Heteroaryl compounds for kinase inhibition |
WO2016021742A1 (en) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
TWI783617B (zh) | 2015-01-09 | 2022-11-11 | 日商小野藥品工業股份有限公司 | 三環性螺化合物之用途 |
JP6689297B2 (ja) | 2015-07-23 | 2020-04-28 | 武田薬品工業株式会社 | 複素環化合物 |
WO2017066633A1 (en) | 2015-10-16 | 2017-04-20 | Eisai R&D Management Co., Ltd. | Ep4 antagonists |
CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
ES2938210T3 (es) | 2016-07-13 | 2023-04-05 | Vertex Pharma | Métodos, composiciones y kits para aumentar la eficiencia de edición del genoma |
JP7093791B2 (ja) | 2017-05-18 | 2022-06-30 | イドーシア ファーマシューティカルズ リミテッド | Pge2レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体 |
WO2018210992A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
KR102626982B1 (ko) | 2017-05-18 | 2024-01-18 | 이도르시아 파마슈티컬스 리미티드 | Pge2 수용체 조절제로서의 피리미딘 유도체 |
HRP20211532T1 (hr) | 2017-05-18 | 2022-01-07 | Idorsia Pharmaceuticals Ltd | N-supstituirani derivati indola |
-
2018
- 2018-05-17 CN CN201880031321.4A patent/CN110612296A/zh active Pending
- 2018-05-17 PT PT18725222T patent/PT3625222T/pt unknown
- 2018-05-17 AR ARP180101315A patent/AR111941A1/es unknown
- 2018-05-17 LT LTEPPCT/EP2018/062862T patent/LT3625222T/lt unknown
- 2018-05-17 CA CA3060597A patent/CA3060597A1/en active Pending
- 2018-05-17 EP EP18725222.6A patent/EP3625222B1/en active Active
- 2018-05-17 KR KR1020197037298A patent/KR102632028B1/ko active IP Right Grant
- 2018-05-17 RS RS20211256A patent/RS62440B1/sr unknown
- 2018-05-17 UA UAA201911975A patent/UA125123C2/uk unknown
- 2018-05-17 MA MA49126A patent/MA49126B1/fr unknown
- 2018-05-17 TW TW107116759A patent/TWI765041B/zh not_active IP Right Cessation
- 2018-05-17 WO PCT/EP2018/062862 patent/WO2018210994A1/en unknown
- 2018-05-17 MX MX2019013718A patent/MX2019013718A/es unknown
- 2018-05-17 JP JP2019563491A patent/JP7159214B2/ja active Active
- 2018-05-17 SI SI201830422T patent/SI3625222T1/sl unknown
- 2018-05-17 HR HRP20211533TT patent/HRP20211533T1/hr unknown
- 2018-05-17 SG SG11201908729U patent/SG11201908729UA/en unknown
- 2018-05-17 CR CR20190559A patent/CR20190559A/es unknown
- 2018-05-17 PL PL18725222T patent/PL3625222T3/pl unknown
- 2018-05-17 US US16/614,594 patent/US11712438B2/en active Active
- 2018-05-17 PE PE2019002396A patent/PE20191814A1/es unknown
- 2018-05-17 AU AU2018269666A patent/AU2018269666B2/en not_active Ceased
- 2018-05-17 IL IL270623A patent/IL270623B2/en unknown
- 2018-05-17 HU HUE18725222A patent/HUE056080T2/hu unknown
- 2018-05-17 DK DK18725222.6T patent/DK3625222T3/da active
- 2018-05-17 EA EA201992676A patent/EA201992676A1/ru unknown
- 2018-05-17 BR BR112019024109-4A patent/BR112019024109A2/pt unknown
- 2018-05-17 ES ES18725222T patent/ES2893452T3/es active Active
-
2019
- 2019-09-27 CO CONC2019/0010578A patent/CO2019010578A2/es unknown
- 2019-11-15 CL CL2019003275A patent/CL2019003275A1/es unknown
- 2019-11-15 PH PH12019502563A patent/PH12019502563A1/en unknown
-
2021
- 2021-10-19 CY CY20211100906T patent/CY1124608T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502563A1 (en) | Phenyl derivatives as pge2 receptor modulators | |
PH12019502564A1 (en) | Pyrimidine derivatives as pge2 receptor modulators | |
PH12018501077A1 (en) | N-substituted indole derivatives as pge2 receptor modulators | |
EA201990851A1 (ru) | Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5 | |
MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
PH12019502562A1 (en) | N-substituted indole derivatives | |
EA201892734A1 (ru) | ПРОИЗВОДНЫЕ АЗАБЕНЗИМИДАЗОЛА В КАЧЕСТВЕ ИНГИБИТОРОВ pI3K BETA | |
EA201690752A1 (ru) | Ингибиторы g12c kras | |
MX363127B (es) | Derivados de benzotiofeno como inhibidores del receptor de estrogeno. | |
MY159059A (en) | 2-amino-4-arylthiazole compounds as trpa1 antagonists | |
EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
CA2891755C (en) | Substituted pyrido-piperazinone derivatives as gamma secretase modulators | |
MX364400B (es) | Compuestos de tetraciclina. | |
PH12015502632A1 (en) | Cxcr7 receptor modulators | |
ZA202109194B (en) | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator | |
MX2020000144A (es) | Composicion farmaceutica para administracion nasal. | |
MX2019012380A (es) | Cristales de compuesto piranodipiridinico. | |
PH12020550124A1 (en) | Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor | |
JOP20180057A1 (ar) | مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6 |